

# Ubiquitous *Brms1* expression is critical for mammary carcinoma metastasis suppression via promotion of apoptosis

Leah M. Cook · Xuemei Cao · Alexander E. Dowell · Michael T. Debies ·  
Mick D. Edmonds · Benjamin H. Beck · Robert A. Kesterson · Renee A. Desmond ·  
Andra R. Frost · Douglas R. Hurst · Danny R. Welch

Received: 31 October 2011 / Accepted: 2 January 2012 / Published online: 13 January 2012  
© Springer Science+Business Media B.V. 2012

**Abstract** Morbidity and mortality of breast cancer patients are drastically increased when primary tumor cells are able to spread to distant sites and proliferate to become secondary lesions. Effective treatment of metastatic disease has been limited; therefore, an increased molecular understanding to identify biomarkers and therapeutic targets is needed. Breast cancer metastasis suppressor 1 (BRMS1) suppresses development of pulmonary metastases when expressed in a variety of cancer types, including metastatic mammary carcinoma. Little is known of *Brms1* function throughout the initiation and progression of mammary carcinoma. The goal of this study was to investigate mechanisms of *Brms1*-mediated metastasis suppression in transgenic mice that express *Brms1* using polyoma middle

T oncogene-induced models. *Brms1* expression did not significantly alter growth of the primary tumors. When expressed ubiquitously using a  $\beta$ -actin promoter, *Brms1* suppressed pulmonary metastasis and promoted apoptosis of tumor cells located in the lungs but not in the mammary glands. Surprisingly, selective expression of *Brms1* in the mammary gland using the MMTV promoter did not significantly block metastasis nor did it promote apoptosis in the mammary glands or lung, despite MMTV-induced expression within the lungs. These results strongly suggest that cell type-specific over-expression of *Brms1* is important for *Brms1*-mediated metastasis suppression.

**Keywords** Metastasis · BRMS1 · PyMT · Transgenic · MMTV · Ubiquitous · Apoptosis · Breast cancer · Mouse · Mammary · Tumor microenvironment

**Electronic supplementary material** The online version of this article (doi:10.1007/s10585-012-9452-x) contains supplementary material, which is available to authorized users.

L. M. Cook · X. Cao · M. D. Edmonds ·  
B. H. Beck · A. R. Frost · D. R. Hurst (✉) · D. R. Welch  
Department of Pathology, University of Alabama at  
Birmingham, 1670 University Blvd., VH-G019, Birmingham,  
AL 35294, USA  
e-mail: dhurst@uab.edu

X. Cao · M. T. Debies · D. R. Welch (✉)  
Department of Cancer Biology, The Kansas University Medical  
Center, 3901 Rainbow Blvd., Robinson 4030, Kansas City, KS  
66160, USA  
e-mail: dwelch@kumc.edu

A. E. Dowell · R. A. Desmond  
Department of Medicine, University of Alabama at Birmingham,  
Birmingham, AL, USA

R. A. Kesterson  
Department of Genetics, University of Alabama at Birmingham,  
Birmingham, AL, USA

R. A. Kesterson · R. A. Desmond · A. R. Frost ·  
D. R. Hurst · D. R. Welch  
Comprehensive Cancer Center, University of Alabama at  
Birmingham, Birmingham, AL, USA

A. R. Frost · D. R. Welch  
Department of Cell Biology, University of Alabama at  
Birmingham, Birmingham, AL, USA

D. R. Welch  
Department of Pharmacology and Toxicology, University of  
Alabama at Birmingham, Birmingham, AL, USA

D. R. Welch  
University of Kansas Cancer Center, The Kansas University  
Medical Center, Kansas City, KS, USA

## Abbreviations

BRMS1	Breast cancer metastasis suppressor 1
PyMT	Polyoma middle T antigen
MMTV	Mouse mammary tumor virus
CMV	Cytomegalovirus
Ubqs	Ubiquitous
DAB	3,3'-Diaminobenzidine
TUNEL	Terminal deoxynucleotidyl transferase dUTP nick end labeling
TdT	Terminal deoxynucleotidyl transferase
NFκB	Nuclear factor kappa B
HDAC	Histone deacetylase
Tg	Transgenic
Wt	Wild-type

## Introduction

Metastasis is the most lethal attribute of breast cancers. Metastases are typically inoperable, difficult to target for treatment, and directly contribute to increased morbidity and mortality of breast cancer. Continuous improvements in early detection methods and treatments have contributed to 5-year breast cancer survival rates approaching 100%. However, survival rates are drastically reduced below 25% upon development of distant metastases [1]. An improved understanding of the molecular mechanisms of metastasis is necessary for identification of novel treatment strategies.

In recent years there has been an increasing appreciation for metastasis suppressors which have provided necessary tools to dissect the molecular underpinnings of metastasis [2, 3]. Breast cancer metastasis suppressor 1 (*BRMS1*) significantly reduces lung metastases in athymic mice when expression is ectopically restored in human metastatic cell lines from breast [4], melanoma [5], ovarian [6], and non-small cell lung carcinomas [7]. *BRMS1* alters multiple cellular pathways involved in metastasis including: gap junctional intercellular communication [7–10], phosphoinositide pools and signaling [11, 12], modification of nuclear factor kappa B (NFκB) signaling [13–15], and cellular motility and invasion [5, 6, 15, 16]. In addition to these changes, Phadke et al. [17] demonstrated that *BRMS1* expression decreased disseminated tumor cell viability and cell seeding in vivo, phenomena consistent with in vitro activation of pro-apoptotic signaling via caspase 3 and PARP cleavage.

Mediation of these pathways is likely attributed to *BRMS1*-regulated gene transcription via *BRMS1* interactions with SIN3: histone deacetylase (HDAC) chromatin remodeling complexes through direct interaction with AT-rich interacting domain 4A (ARID4A) and suppressor of defective silencing 3 (SUDS3) [18, 19]. Although there is no evidence of *BRMS1* functioning as a transcription

factor, *BRMS1* has been shown to recruit HDAC1, and presumably SIN3 complexes, to NFκB consensus regions leading to inhibition of NFκB activity [15, 20].

*BRMS1* orthologs are highly conserved across many species. Especially pertinent to this study, the amino acid sequence of murine *Brms1* is 95% homologous with human *BRMS1* [21]. When re-expressed in 4T1 or 66cl4 metastatic mammary carcinoma cells, *Brms1* significantly reduced metastases to the lungs in syngeneic BALB/c mice [22]. Furthermore, murine *Brms1* associates with HDAC1 affirming functional similarity to human *BRMS1*, warranting its use in genetically-engineered mice to further investigate mechanisms of action in metastasis suppression.

Although restoration-of-expression experiments have been useful in xenograft and syngeneic models, these experimental systems do not fully recapitulate initiation and progression of malignancy and host-tumor interactions that occur throughout tumor progression [23, 24]. Development of *Brms1* metastasis models in which tumors arise de novo and spontaneously metastasize (by utilizing genetically-engineered mice) provides new insight into mechanisms of metastasis suppression. We developed two transgenic mouse models which over-express *Brms1*. The first, *Brms1*<sup>MMTV</sup>, selectively expresses *Brms1* in mammary glands using the mouse mammary tumor virus (MMTV) promoter. In the second, *Brms1*<sup>Ubqs</sup>, *Brms1* is expressed ubiquitously using the cytomegalovirus (CMV)-enhanced chicken beta actin promoter. Both models were used to test the impact of *Brms1* over-expression on primary tumor development and metastatic potential by crossing them with the well-characterized polyoma middle T (PyMT) oncogene mammary tumor mouse model [25, 26]. As predicted, *Brms1* function as a metastasis suppressor was affirmed in the *Brms1*<sup>Ubqs</sup> × MMTV-PyMT F<sub>1</sub> mice. Surprisingly, F<sub>1</sub> generation mice from *Brms1*<sup>MMTV</sup> × MMTV-PyMT still developed metastases at similar levels to PyMT mice. These results reveal a more complex mode of action for *Brms1*-mediated metastasis suppression than was previously recognized.

## Materials and methods

### Mouse husbandry and analysis

All animal studies were carried out under the approval of the University of Alabama at Birmingham (UAB) Institutional Animal Care and Use Committee (IACUC). For mammary-selective expression of *Brms1* cDNA, the 8.4 kb pMAMneo mammalian expression vector which contains the RSV-LTR enhancer linked to the MMTV-LTR promoter was utilized. The vector contains the RSV-LTR enhancer linked to the MMTV-LTR promoter. The ubiquitous *Brms1* expresser (*Brms1*<sup>Ubqs</sup>) expresses *Brms1* in

most tissues by the CMV-enhanced chicken  $\beta$ -actin promoter (CAG promoter). To generate *Brms1*<sup>Ubq</sup> mice, the pCX expression vector carrying the CAG promoter (a combination of the CMV early enhancer element and chicken  $\beta$ -actin promoter) was utilized. All pronuclear injections were performed by the UAB Transgenic Core and resulting chimera were mated with wild-type C57BL/6 mice resulting in heterozygous *Brms1* transgenic mice. PyMT oncogene transgenic mice were obtained from Jackson Laboratories (Bar Harbor, ME).

All mice were tail-clipped, weaned (at ~3 weeks), and genotyped. Transgenic *Brms1* mice were genotyped by PCR using the following primers: GCCAACTGAGTCAGAG GAG and GTGTTGTTGGCTCCCTG. Transgene presence was identified by the presence of two genetic bands, one 720 bp endogenous *Brms1* band and a 275 bp *Brms1* cDNA band. PyMT mice were genotyped by PCR using the following primers: AACGGCGGAGCGAGGAACTG and ATCGGGCTCAGCAACACAAG. Transgenic mice were identified by the presence of a 556 bp genetic band. To validate increased *Brms1* expression, normal mammary gland and lung tissues from transgenic *Brms1* mice were collected, flash-frozen using liquid nitrogen, and expression was analyzed using real-time quantitative reverse transcription PCR (RT-qPCR).

Because heterozygous PyMT<sup>+/-</sup> females develop benign hyperplastic lesions at puberty and cannot effectively nurse pups, heterozygous males were crossed with heterozygous *Brms1*<sup>tg/wt</sup> (transgenic) females to yield an F1 generation. PyMT<sup>+/-</sup>/*Brms1*<sup>wt</sup> mice expressed endogenous levels of wild-type *Brms1*, PyMT<sup>+/-</sup>/*Brms1*<sup>tg/wt</sup> mice expressed the *Brms1* transgene expression, and PyMT<sup>-/-</sup>/*Brms1*<sup>wt</sup> and PyMT<sup>-/-</sup>/*Brms1*<sup>tg/wt</sup> mice expressed wild-type and transgenic *Brms1*, respectively, in the absence of the *PyMT* oncogene. When possible, PyMT<sup>+/-</sup>/*Brms1*<sup>wt</sup> and PyMT<sup>+/-</sup>/*Brms1*<sup>tg/wt</sup> littermates were compared for tumorigenicity and metastatic potential.

Mice were monitored daily and incidence of the first tumor appearance was recorded. Body weight and total tumor burden were determined at necropsy. Normal mammary glands and mammary tumors were flash-frozen using liquid nitrogen for gene and protein analyses. In addition, aliquots of tumor tissue were formalin-fixed and paraffin-embedded for histological analyses. Tissues were processed, sectioned and either stained with hematoxylin and eosin or utilized for immunohistochemical assays. Lungs were dissected and fixed in either Bouin's fixative or formalin-fixed and paraffin-embedded for histology. The number of lung metastases was counted by visual inspection of fixed lungs and by histological analysis. The number of macroscopic metastases in PyMT<sup>+/-</sup>/*Brms1*<sup>tg/wt</sup> was compared to control mice (PyMT<sup>+/-</sup>/*Brms1*<sup>wt</sup>) to determine changes in metastatic potential that occurred due to

*Brms1* over-expression. Liver, spleen, and kidney were also collected and analyzed for the presence of metastases in other organs in addition to the lungs. When possible, littermates were compared as described above.

#### Real-time quantitative reverse-transcription PCR

Flash-frozen tissue was homogenized by mortar and pestle and lysed with Qiazol Lysis Reagent (Qiagen, Valencia, CA). RNA was isolated using the miRNEasy extraction kit (Qiagen) according to the manufacturer's protocol, reverse-transcribed and quantified using the miScript SYBR Green PCR kit (Qiagen) and *Brms1*-specific Quantitect Assay primers (Qiagen). Relative RNA expression in all samples was normalized to 18s rRNA expression levels and fold-change was calculated as previously described [27].

#### Immunohistochemistry

For immunohistochemical analyses of proliferation and microvessel density, 5  $\mu$ m thick sections of formalin-fixed, paraffin-embedded mammary tumor tissue sections were deparaffinized in xylene and rehydrated in graded alcohols. For antigen retrieval, slides were immersed and boiled for 20 min in a diluted (1:30), pH 9.0, antigen unmasking solution (Vector Laboratories, Burlingame, CA). Slides were incubated in a horse serum blocking solution (ImmPRESS system, Vector Laboratories) for 1 h followed by incubation with either Ki67 primary monoclonal antibody (Clone TEC3 Antigen, 1:100 dilution, Dako, Carpinteria, CA) or CD31 primary polyclonal antibody (Ab28364, 1:100 dilution, AbCam, Cambridge, MA) in phosphate-buffered saline solution containing 1% bovine serum albumin. Appropriate secondary antibody (ImmPRESS, Vector Laboratories) was applied and slides were incubated in DAB (3,3'-diaminobenzidine) peroxidase substrate solution (Dako). Each slide was then incubated with Harris hematoxylin counterstain (Fisher Scientific, Waltham, MA). Nuclei of cells positive for Ki67 stained brown and the percentage of positive cells per high powered microscopic field was determined. A minimum of 1,000 cells were counted for each mammary tumor sample. Intratumoral microvascular density (iMVD) was determined by averaging the number of CD31-positive vessels in representative areas with the highest microvessel density (designated "hot spots") as previously described [28]. A minimum of three "hot spots" were counted per sample. To assess iMVD in metastases, the total number of CD31-positive vessels was counted per metastatic lesion per sample. Only lesions containing more than 500 cells were assessed for iMVD to analyze changes in angiogenesis due to potentially hypoxic conditions.

For analyses of apoptosis in tumor and lung tissue, the ApopTag Plus Peroxidase In Situ Apoptosis Detection Kit

(Millipore, Billerica, MA) was utilized according to the manufacturer's protocol. Apoptotic bodies/nuclei were stained brown with DAB peroxidase substrate and the percentage of positive cells within the primary tumor per high powered microscopic field was determined as described above. The percentage of total positive cells per metastatic lesion was determined.


### Statistical analysis

Continuous parameters were compared by the student's *t* test for body weight, age at necropsy, and number of metastases when controlling for age. The primary endpoint of interest was the number of visible lung macroscopic metastases in each genotype group. Due to a non-normal distribution, the median test was used to compare the total number of lung metastases per group. Because metastatic potential correlates with total tumor burden in PyMT mice, a multivariable analysis for number of lung metastases was conducted using generalized Poisson regression. Age was used as an offset variable in the multivariable model because some of the animals were euthanized early due to high tumor burden which may have affected the number of metastases. Tumor latency was calculated as the percentage of tumor-free mice throughout the study using Kaplan–Meier analyses. Data from tumor latency studies were analyzed by non-parametric Wilcoxon rank sum test. Tumor burden, proliferation, and apoptosis studies were analyzed by two-sample paired student's *t* test assuming equal variance. All analyses were performed using SAS (Ver. 9.2<sup>®</sup>) statistical analysis software. A *P* value <0.05 was deemed statistically significant.

## Results

### *Brms1* expression is increased in transgenic mice

To validate increased *Brms1* expression, RT-qPCR analysis was performed on normal mammary gland and lung tissues from ubiquitous and mammary-selective transgenic *Brms1* mice. Both *Brms1*<sup>MMTV</sup> (*P* = 0.31) and *Brms1*<sup>Ubqs</sup> mice (*P* = 0.01) exhibited an increase of *Brms1* expression in mammary gland compared to wild-type C57BL/6 mice (Fig. 1a). Although *Brms1* should be over-expressed in all tissues in *Brms1*<sup>Ubqs</sup> mice, we focused on expression in the major tissues involved in the PyMT mammary tumor model—mammary glands and lungs. As expected, *Brms1* expression in lungs of *Brms1*<sup>Ubqs</sup> mice was five times greater than observed in wild-type mice (*P* = 0.02) (Fig. 1b). *Brms1* was also increased in lung tissue of *Brms1*<sup>MMTV</sup> mice (*P* = 0.04), confirming previous reports of “leaky” expression of the MMTV promoter [29].




**Fig. 1** *Brms1* expression is increased in transgenic mice. Two-step RT-qPCR using SYBRGreen was utilized to detect *Brms1* in normal mouse tissues. Relative expression is graphed as fold change compared to wild-type control. All samples were normalized to ribosomal 18S RNA. **a** Relative expression of *Brms1* in normal mammary gland tissue from wild-type (*Brms1*<sup>wt</sup>), mammary-selective (*Brms1*<sup>MMTV</sup>; *P* = 0.31), and ubiquitous *Brms1* mice (*Brms1*<sup>Ubqs</sup>; *P* = 0.01). **b** Relative expression of *Brms1* in normal lung from wild-type (*Brms1*<sup>wt</sup>), mammary-selective (*Brms1*<sup>MMTV</sup>; *P* = 0.04), and ubiquitous *Brms1* mice (*Brms1*<sup>Ubqs</sup>; *P* = 0.02). Statistical analysis was performed using student's two sample *t* test assuming equal variance. Error bars standard error of the mean for biological replicates (triplicate)

### Increased *Brms1* expression does not significantly alter tumor latency or growth

Female F<sub>1</sub> crossed mice (litter of PyMT<sup>+/-</sup> × *Brms1*<sup>tg/wt</sup>) were compared for analysis of tumor and metastasis development. As previously demonstrated [25, 26], all mice expressing the PyMT oncogene developed mammary carcinoma in multiple (sometimes all 10) mammary glands. As expected, PyMT<sup>-/-</sup> × *Brms1*<sup>Ubqs</sup> and PyMT<sup>-/-</sup> × *Brms1*<sup>MMTV</sup> littermates did not spontaneously develop tumors. There were no significant differences in tumor latency when comparing control mice (PyMT<sup>+/-</sup>/*Brms1*<sup>wt</sup>) to tumor-bearing transgenic *Brms1* mice (PyMT<sup>+/-</sup>/*Brms1*<sup>MMTV</sup> or PyMT<sup>+/-</sup>/*Brms1*<sup>Ubqs</sup>) (Fig. 2a, b). All mice





**Fig. 2** Tumor latency and mass are not significantly altered by *Brms1* over-expression in autochthonous primary tumors. Mice were palpated weekly and date of first palpable tumor was recorded as tumor latency. **a** and **b** survival analyses of tumor-bearing mice comparing controls (PyMT<sup>+/-</sup>/Brms1<sup>wt</sup>) and transgenic *Brms1* mice (PyMT<sup>+/-</sup>/Brms1<sup>MMTV</sup> and PyMT<sup>+/-</sup>/Brms1<sup>Ubqs</sup>). Tumor onset is represented by percentage of tumor-free mice throughout the study. Non-parametric Wilcoxon rank sum analysis revealed no significant change in tumor latency. Brms1<sup>MMTV</sup> and Brms1<sup>Ubqs</sup> denote F<sub>1</sub> crossed mice of PyMT<sup>+/-</sup> × Brms1<sup>MMTV</sup> and PyMT<sup>+/-</sup> × Brms1<sup>Ubqs</sup>, respectively. **c** and **d** Two-step RT-qPCR (as described in Materials and methods) comparing expression of *Brms1* in primary

tumors from PyMT<sup>+/-</sup>/Brms1<sup>wt</sup>, PyMT<sup>+/-</sup>/Brms1<sup>MMTV</sup>, and PyMT<sup>+/-</sup>/Brms1<sup>Ubqs</sup>. Relative expression is graphed as fold change compared to control mice, PyMT<sup>+/-</sup>/Brms1<sup>wt</sup>. All samples were normalized to ribosomal 18S RNA. Error bars standard error of the mean for biological replicates (triplicate). **e** and **f** Tumors were removed and collectively weighed to determine overall tumor burden. Graphs average total tumor mass per group. Statistical analysis using two-sample student's *t* test revealed no significant differences in total primary tumor burden per mouse when comparing transgenic PyMT<sup>+/-</sup>/Brms1<sup>MMTV</sup> ( $P = 0.94$ ) and PyMT<sup>+/-</sup>/Brms1<sup>Ubqs</sup> ( $P = 0.80$ ) with respective controls. Error bars standard error of the mean for biological replicates

developed palpable tumors at approximately 12–14 weeks of age. There were no differences in tumor or lung pathology when comparing controls to either *Brms1* over-expressing mice (Supplemental Fig. 1). Analysis of primary mammary tumors isolated from PyMT<sup>+/-</sup>/Brms1<sup>Ubqs</sup> or PyMT<sup>+/-</sup>/Brms1<sup>MMTV</sup> revealed increased *Brms1* expression in tumors from transgenic mice compared to tumors from PyMT<sup>+/-</sup>/Brms1<sup>wt</sup> controls (Fig. 2c, d). There were no significant differences in the total primary tumor burden per mouse (i.e. mass of all mammary tumors combined) when comparing PyMT<sup>+/-</sup>/Brms1<sup>Ubqs</sup> or PyMT<sup>+/-</sup>/Brms1<sup>MMTV</sup> mice with respective controls (Fig. 2e, f; Table 1).

Ubiquitous *Brms1* expression significantly suppresses lung metastases

To assess the impact of *Brms1* over-expression on metastasis of PyMT-induced mammary carcinoma, lungs were collected from PyMT<sup>+/-</sup>/Brms1<sup>wt</sup>, PyMT<sup>+/-</sup>/Brms1<sup>MMTV</sup>, and PyMT<sup>+/-</sup>/Brms1<sup>Ubqs</sup> mice and macroscopic metastases were counted with a dissecting microscope. Over-expression of *Brms1* predominantly in mammary tissue, PyMT<sup>+/-</sup>/Brms1<sup>MMTV</sup>, did not significantly alter the median number of macroscopic lung metastases ( $P = 0.78$ ; Fig. 3a; Table 1) when compared to PyMT<sup>+/-</sup>/Brms1<sup>wt</sup> controls. There was

**Table 1** Descriptive statistics for tumors and metastases in PyMT<sup>+/-</sup> × transgenic *Brms1* over-expressing mice

Parameter	PyMT <sup>+/-</sup> /Brms1 <sup>wt</sup> (n = 19)		PyMT <sup>+/-</sup> /Brms1 <sup>MMTV</sup> (n = 47)	
	Median	Range	Median	Range
Body weight (g)	30.9	21.7–56.0	29.4	20.7–56.0
Age at euthanasia (wk)	17.0	15–19	16	13–19
Tumor burden (g)	5.0	2.3–18.9	6.0	0.0–18.9
No. macroscopic lung metastases	6	0–136	5	0–136
Parameter	PyMT <sup>+/-</sup> /Brms1 <sup>wt</sup> (n = 17)		PyMT <sup>+/-</sup> /Brms1 <sup>Ubqs</sup> (n = 11)	
	Median	Range	Median	Range
Body weight (g)	29.0	23.0–47.3	31.0	24.8–35.8
Age at euthanasia (wk)	18	12–22	19	14–21
Tumor mass (g)	6.4	2.2–23.9	9.4	5.3–13.1
No. macroscopic lung metastases	31	0–223	8	0–146

There is a known tendency for the mice to reduce aggressiveness if bred for prolonged times. We observed this during the Brms1<sup>MMTV</sup> crosses. Therefore, MMTV-PyMT mice were re-derived by the supplier and purchased by us for the Brms1<sup>Ubqs</sup> crosses. This is why there is an apparent increase in basal metastatic potential

no significant difference in the number of metastases in PyMT<sup>+/-</sup>/Brms1<sup>MMTV</sup> mice when controlled for overall tumor mass and age at necropsy ( $P = 0.63$ ) in a multivariable analysis.

However, ubiquitous over-expression of *Brms1*, PyMT<sup>+/-</sup>/Brms1<sup>Ubqs</sup>, reduced the number of visible lung metastases compared to PyMT<sup>+/-</sup>/Brms1<sup>wt</sup> controls. The median number of metastases was higher in the control mice (median = 31) compared to the Brms1<sup>Ubqs</sup> mice (median = 8;  $P = 0.06$ ) (Fig. 3b, c; Table 1). Subsequently, Brms1<sup>Ubqs</sup> mice had significantly fewer metastases at necropsy in a multivariable analysis controlling for total tumor burden and age at necropsy ( $P < 0.0001$ ). H&E stained lung sections revealed no gross morphological differences when comparing metastatic lesions from Brms1<sup>Ubqs</sup> and control mice (Supplemental Fig. 1). As in the control mice, PyMT<sup>+/-</sup>/Brms1<sup>MMTV</sup> and PyMT<sup>+/-</sup>/Brms1<sup>Ubqs</sup> mice had no macroscopic nor microscopic metastases in liver, spleen, or kidney (Supplemental Fig. 2). There were no differences in the size of metastatic lesions in the lungs of PyMT<sup>+/-</sup>/Brms1<sup>MMTV</sup> or PyMT<sup>+/-</sup>/Brms1<sup>Ubqs</sup> when compared to respective control mice. To determine whether metastasis suppression was related to alterations that occurred in the primary tumor, proliferation, apoptosis and microvascular density were measured. No significant changes were found (Fig. 4a–c).

Ubiquitous *Brms1* expression induces apoptosis in lung metastases


Apoptosis was analyzed by TUNEL staining to determine whether ubiquitous expression of *Brms1* altered apoptosis within metastatic lung lesions. Metastatic foci from PyMT<sup>+/-</sup>/Brms1<sup>Ubqs</sup> mice exhibited a 3-fold higher

apoptosis compared to PyMT<sup>+/-</sup>/Brms1<sup>wt</sup> littermates (Fig. 5a, c). There was no significant change in microvessel density within the lung metastases of PyMT<sup>+/-</sup>/Brms1<sup>Ubqs</sup> mice (data not shown), suggesting that induction of apoptosis was independent of angiogenesis. Despite increased *Brms1* expression in PyMT<sup>+/-</sup>/Brms1<sup>MMTV</sup> lungs, there was no significant difference in apoptosis of PyMT<sup>+/-</sup>/Brms1<sup>MMTV</sup> lung lesions when compared to control PyMT<sup>+/-</sup>/Brms1<sup>wt</sup> mice (Fig. 5b).

## Discussion

For decades, researchers have sought to fully understand the genetic complexities involved in the development and progression of breast carcinoma, including how the host-tumor interactions can potentiate or inhibit tumor progression. Understanding how tumor cells adapt to changing environments, including their ability to survive and proliferate in foreign tissues (i.e. ectopic sites), is important for identification of relevant targets for metastatic disease. These are the first studies to reveal that *Brms1* function, as an important mediator of apoptosis and metastasis, may be context-dependent and rely on specific cell-type expression.

Consistent with the definition of a metastasis suppressor, *Brms1* over-expression did not discernibly affect primary tumor incidence or growth. When expressed ubiquitously, *Brms1* suppressed metastasis and induced apoptosis when tumor cells seeded the lungs. The pro-apoptotic effect occurred independently of angiogenic properties and was not reflected in similar analyses of corresponding primary tumors. However, it had been previously shown that BRMS1 could potentiate apoptosis in vitro, sensitize tumor




**Fig. 3** Ubiquitous expression of *Brms1* significantly suppresses lung metastases. Lungs were removed from each mouse and fixed in Bouin's fixative. Visible metastases were counted using a dissecting microscope. **a** Scatter plot number of metastases per mouse. The red line median number of visible metastases in control mice,  $PyMT^{+/-}/Brms1^{wt}$  ( $n = 19$ ) (median = 6) and  $PyMT^{+/-}/Brms1^{MMTV}$  ( $n = 47$ ) (median = 5), respectively. There was no significant difference in the median number of lung metastases. **b** Scatter plot number of metastases per mouse. Red and blue line represents median number of visible metastases in control mice,  $PyMT^{+/-}/Brms1^{wt}$  ( $n = 17$ ) (median = 31) and  $PyMT^{+/-}/Brms1^{MMTV}$  ( $n = 11$ ) (median = 8), respectively.  $PyMT^{+/-}/Brms1^{Ubqs}$  exhibited fewer metastases when compared to controls,  $PyMT^{+/-}/Brms1^{wt}$ . Poisson regression controlling for age and total tumor burden at necropsy revealed a significant reduction in  $PyMT^{+/-}/Brms1^{Ubqs}$  mice ( $P < 0.0001$ ). **c** Representative images of lungs collected from control and  $PyMT^{+/-}/Brms1^{Ubqs}$  mice (dorsal and ventral views of same lung). White arrows highlight visible metastases

cells to anoikis in vivo, and correlate with expression of pro-apoptotic genes in clinical samples of breast cancer patients [15, 17, 30]. The data presented in this report suggest that *BRMS1* over-expression within the microenvironment where metastases form (i.e. lung parenchyma) could be just as important for induction of tumor cell apoptosis. In support of this notion, several studies have reported that conditioned media from cultured normal lung fragments induced anti-apoptotic signaling [31] or increased the survival of metastatic mammary carcinoma cells [32], implying that the lung microenvironment can facilitate tumor cell survival. Over-expression of *Brms1* in certain environments may reverse those effects. However, the situation may be more complex and depend on specific cell-type expression since *Brms1* was also over-expressed in the lungs of  $Brms1^{MMTV}$  mice.

Taken together, our findings suggest a potential role for stromal *Brms1* expression as a modulator of metastasis. Inhibition of stromal cell signaling appears to be essential for suppression of metastasis by PyMT-derived tumors which rely, in part, on stromal-associated promotion of tumor cell migration, invasion, and metastasis [33–37]. The MMTV promoter (utilized in PyMT and  $Brms1^{MMTV}$  mice) drives expression within epithelial cells whereas the CMV-enhanced chicken  $\beta$ -actin promoter (utilized in  $Brms1^{Ubqs}$  mice) drives expression in both stromal and epithelial cells). Because MMTV-induced *Brms1* expression neither suppressed metastasis nor induced apoptosis within metastatic lesions, it appears that *Brms1* expression within both stromal and epithelial cells is necessary for both phenotypes. But, additional studies will be necessary to test this hypothesis directly.

It remains unclear why *Brms1* expression in mammary epithelium was not sufficient for metastasis suppression. Prior investigations utilizing xenograft and syngeneic models involved restoration of *BRMS1* expression in metastatic cells, i.e. cells which have already overcome outstanding limitations in progression. The autochthonous models utilized here include initiation and progression of mammary carcinomas in a continuously evolving tumor microenvironment and constitutively expressed PyMT and *Brms1*. Although the findings reported here seemingly contradict transfection and over-expression data, one must consider the dynamics of mammary stromal-epithelial interactions that occur throughout mammary carcinoma progression [38]. The stroma regulates mammary epithelial growth, glandular development and homeostasis. Upon transformation and disease progression, tumor cells bypass stromal regulation and recruit new stromal constituents that modulate the microenvironment to support continuous growth and development [39]. While tumor-stromal interactions are undoubtedly relevant in the injection models, the developmental time line is attenuated and does not fully recapitulate the impact of an evolving microenvironment



**Fig. 4** *Brms1* does not alter primary tumor proliferation, apoptosis, or intratumoral microvessel density (iMVD). Proliferation and iMVD were analyzed by IHC using antibodies to the proliferation marker, Ki67, and CD31, a marker for blood vessels. Apoptosis was analyzed using TUNEL assay. Changes were determined by percentage positive cells (stained brown via DAB peroxidase substrate) per high-powered microscopic field. Analysis was performed via ImageJ software. *Brms1*<sup>Ubqs</sup> denotes F<sub>1</sub> crossed mice of PyMT<sup>+/-</sup> × *Brms1*<sup>Ubqs</sup>. **a** Graph percentage of Ki67-positive cells in primary mammary tumors from transgenic *Brms1* mice, PyMT<sup>+/-</sup>/*Brms1*<sup>Ubqs</sup> mice ( $n = 8$ ) normalized to control mice, PyMT<sup>+/-</sup>/*Brms1*<sup>wt</sup> ( $n = 12$ ). A minimum of 1,000 cells per sample were counted. Statistical analysis using two-sample student's *t* test revealed no significant change ( $P = 0.33$ ). Error bars standard error of the mean


for biological replicates. **b** Graph percentage of TUNEL-stained cells in primary mammary tumors from PyMT<sup>+/-</sup>/*Brms1*<sup>Ubqs</sup> ( $n = 6$ ) normalized to control mice, PyMT<sup>+/-</sup>/*Brms1*<sup>wt</sup> ( $n = 9$ ). Statistical analysis using two-sample student's *t* test revealed no significant change ( $P = 0.97$ ). Error bars standard error of the mean for biological replicates. **c** Graph percentage of CD31-stained cells in primary mammary tumors from PyMT<sup>+/-</sup>/*Brms1*<sup>Ubqs</sup> ( $n = 7$ ) normalized to control mice, PyMT<sup>+/-</sup>/*Brms1*<sup>wt</sup> ( $n = 12$ ). iMVD was determined by averaging the number of CD31-positive vessels in designated “hot spots”. A minimum of three “hot spots” were counted per sample. Statistical analysis using two-sample student's *t* test revealed no significant change ( $P = 0.25$ ). Error bars standard error of the mean for biological replicates

throughout progression. Our findings suggest that the tumor microenvironment and host-tumor interactions play pivotal roles in *Brms1*-mediated metastasis suppression. Collectively, these studies highlight the importance of using multiple model systems to gain a more complete understanding of the mechanisms of metastasis suppression. For example, transplantation of mammary tumors representing different breast cancer molecular subtypes onto transgenic mice could be done. Although planned, those studies are beyond the scope of this initial report.

Another potential explanation for failure of MMTV-driven *Brms1* to suppress metastasis may relate to the expression levels in the transgenic mice. *Brms1* expression in mammary glands of *Brms1* transgenic mice was

analyzed in virgin mice (i.e. when the fat pad is still relatively under-developed and has few epithelial cells compared to the total mass). The normal mammary gland of virginal *Brms1*<sup>MMTV</sup> mice did not exhibit a significant increase in *Brms1* expression. Expression was markedly increased in primary tumors of PyMT<sup>+/-</sup>/*Brms1*<sup>MMTV</sup> mice (and was comparable to expression in PyMT<sup>+/-</sup>/*Brms1*<sup>Ubqs</sup> tumors), which have a greater proportion of epithelium-derived cells compared to the normal mammary gland and which is consistent with the MMTV promoter being expressed only in the epithelial compartment. Perhaps a spatiotemporal (before oncogenesis and throughout progression) or a threshold level of BRMS1 expression is required to suppress metastasis. Generating a panel of mice





**Fig. 5** Ubiquitous expression of *Brms1* significantly induces apoptosis in lung metastases. Apoptosis in lung metastatic lesions was analyzed using TUNEL assay. Changes were determined by percentage positive cells (stained brown via DAB peroxidase substrate) per lesion. Analysis was performed via ImageJ software. Brms1<sup>MMTV</sup> and Brms1<sup>Ubqs</sup> denote F<sub>1</sub> crossed mice of PyMT<sup>+/-</sup> × Brms1<sup>MMTV</sup> and PyMT<sup>+/-</sup> × Brms1<sup>Ubqs</sup>, respectively. **a** Graph average percentage of TUNEL-stained cells in lung metastases in PyMT<sup>+/-</sup>/Brms1<sup>Ubqs</sup> ( $n = 5$ ) mice normalized to control mice, PyMT<sup>+/-</sup>/Brms1<sup>wt</sup> ( $n = 9$ ). Statistical analysis using two-sample student's *t* test revealed a

significant increase in apoptosis in lung metastases of PyMT<sup>+/-</sup>/Brms1<sup>Ubqs</sup> mice ( $P = 0.02$ ). **b** Graph average percentage of TUNEL-stained cells in lung metastases in PyMT<sup>+/-</sup>/Brms1<sup>MMTV</sup> mice ( $n = 6$ ) normalized to control mice, PyMT<sup>+/-</sup>/Brms1<sup>wt</sup> ( $n = 8$ ). Statistical analysis using two-sample student's *t* test revealed no significant change in apoptosis ( $P = 0.79$ ). **c** Representative images of apoptotic bodies in metastases of PyMT<sup>+/-</sup>/Brms1<sup>wt</sup> and PyMT<sup>+/-</sup>/Brms1<sup>Ubqs</sup> mice. The top panels show 200× magnification. Bottom panels (400× magnification) inset within top panels, size bar 50 μm

with a range of *Brms1* expression under temporal control would need to be done in order to evaluate this possibility, but is beyond the scope of this initial report.

Host genetic background is another important factor involved in the development of mammary carcinoma metastasis [40, 41]. The data presented here represent the F<sub>1</sub> generation of the *PyMT* oncogene on an FVB strain crossed with the *Brms1* transgene on the C57BL/6 strain. This is important because Hunter and colleagues showed that the F<sub>1</sub> generation MMTV-*PyMT* × C57BL/6 cross were metastasis suppressed [40, 41]. When this project began, congenic MMTV-*PyMT* on a C57BL/6 background did not exist. They recently became available, allowing assessment of the impact of *Brms1* over-expression on MMTV-*PyMT* independent of background genetic complications. We have initiated these studies but require larger numbers of animals before we can accurately assess or interpret the findings.

Our results provide a potential explanation for inconsistencies reported for *BRMS1* mRNA and protein expression in clinical samples [42–46]. Interpretation of the clinical studies is affected by the purity of sample (i.e. contamination by stromal cells), discordance between mRNA and BRMS1 protein levels and BRMS1 localization in the nucleus versus cytoplasm. The finding that *Brms1*-mediated metastasis suppression may be influenced by expression within the stromal compartment strongly suggests that expression in specific cell types may be more important than expression within primary tumor cells as an indicator of metastatic disease than previously appreciated.

**Acknowledgments** We would like to thank Dr. Clinton Grubbs in the UAB Department of Pharmacology and Toxicology for processing and preparing all histology slides. We are grateful for the counsel of Drs. Terri Wood and Rosa Serra during the course of these studies. We also thank Dr. Monica Richert for aiding in early colony maintenance of our transgenic mice and members of the Welch and Hurst labs for critical reading of the manuscript. We apologize to those whose work could not be cited due to space limitations. This paper is published in partial fulfillment of the requirements of the doctoral dissertation of LMC. Grant Support: National Institutes of Health [CA87728 (DRW), CA134981 (DRW) and CA089019 (DRW & DRH)], National Foundation for Cancer Research (DRW), and Susan G. Komen for the Cure [SAC11037] (DRW); UAB Cancer Prevention and Control Training Grant [CA47888] (LMC); American Cancer Society [RSG-11-259-01-CSM] (DRH). DRW is an Eminent Scholar of the Kansas Biosciences Authority. The Transgenic Mouse Facility and Biostatistics Shared Resources were supported by the UAB Comprehensive Cancer Center core grant P30 CA13148.

**Conflict of interest** We certify there are no conflicts of interest.

## References

1. Siegel R, Ward E, Brawley O et al (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. *CA Cancer J Clin* 61:212–236
2. Cook LM, Hurst DR, Welch DR (2011) Metastasis suppressors and the tumor microenvironment. *Semin Cancer Biol* 21:113–122
3. Hurst DR, Welch DR (2011) Metastasis suppressor genes: at the interface between the environment and tumor cell growth. *Int Rev Cell Mol Biol* 286:107–180
4. Seraj MJ, Samant RS, Verderame MF et al (2000) Functional evidence for a novel human breast carcinoma metastasis suppressor, *BRMS1*, encoded at chromosome 11q13. *Cancer Res* 60:2764–2769
5. Shevde LA, Samant RS, Goldberg SF et al (2002) Suppression of human melanoma metastasis by the metastasis suppressor gene, *BRMS1*. *Exp Cell Res* 273:229–239
6. Zhang S, Lin QD, Di W (2006) Suppression of human ovarian carcinoma metastasis by the metastasis-suppressor gene, *BRMS1*. *Int J Gynecol Cancer* 16:522–531
7. Smith PW, Liu Y, Siefert SA et al (2009) Breast cancer metastasis suppressor 1 (*BRMS1*) suppresses metastasis and correlates with improved patient survival in non-small cell lung cancer. *Cancer Lett* 276:196–203
8. Saunders MM, Seraj MJ, Li ZY et al (2001) Breast cancer metastatic potential correlates with a breakdown in homospic and heterospic gap junctional intercellular communication. *Cancer Res* 61:1765–1767
9. Kapoor P, Saunders MM, Li Z et al (2004) Breast cancer metastatic potential: correlation with increased heterotypic gap junctional intercellular communication between breast cancer cells and osteoblastic cells. *Int J Cancer* 111:693–697
10. Bodenshtein TM, Vaidya KS, Ismail A et al (2010) Homotypic gap junctional communication associated with metastasis suppression increases with PKA activity and is unaffected by PI3K inhibition. *Cancer Res* 70:10002–10011
11. DeWald DB, Torabinejad J, Samant RS et al (2005) Metastasis suppression by breast cancer metastasis suppressor 1 involves reduction of phosphoinositide signaling in MDA-MB-435 breast carcinoma cells. *Cancer Res* 65:713–717
12. Vaidya KS, Harihar S, Stafford LJ et al (2008) Breast cancer metastasis suppressor-1 differentially modulates growth factor signaling. *J Biol Chem* 283:28354–28360
13. Cicek M, Fukuyama R, Welch DR et al (2005) Breast cancer metastasis suppressor 1 inhibits gene expression by targeting nuclear factor-kappaB activity. *Cancer Res* 65:3586–3595
14. Samant RS, Clark DW, Fillmore RA et al (2007) Breast cancer metastasis suppressor 1 (*BRMS1*) inhibits osteopontin transcription by abrogating NF-kappaB activation. *Mol Cancer* 6:6
15. Liu Y, Smith PW, Jones DR (2006) Breast cancer metastasis suppressor 1 functions as a corepressor by enhancing histone deacetylase 1-mediated deacetylation of RelA/p65 and promoting apoptosis. *Mol Cell Biol* 26:8683–8696
16. Samant RS, Seraj MJ, Saunders MM et al (2001) Analysis of mechanisms underlying *BRMS1* suppression of metastasis. *Clin Exp Metastasis* 18:683–693
17. Phadke PA, Vaidya KS, Nash KT et al (2008) *BRMS1* suppresses breast cancer experimental metastasis to multiple organs by inhibiting several steps of the metastatic process. *Am J Pathol* 172:809–817
18. Meehan WJ, Samant RS, Hopper JE et al (2004) Breast cancer metastasis suppressor 1 (*BRMS1*) forms complexes with retinoblastoma-binding protein 1 (*RBP1*) and the mSin3 histone deacetylase complex and represses transcription. *J Biol Chem* 279:1562–1569
19. Hurst DR, Xie Y, Vaidya KS et al (2008) Alterations of *BRMS1*–*ARID4A* interaction modify gene expression but still suppress metastasis in human breast cancer cells. *J Biol Chem* 283:7438–7444
20. Cicek M, Fukuyama R, Cicek MS et al (2009) *BRMS1* contributes to the negative regulation of *uPA* gene expression through

- recruitment of HDAC1 to the NF-kappaB binding site of the uPA promoter. Clin Exp Metastasis 26:229–237
21. Samant RS, Debies MT, Shevde LA et al (2002) Identification and characterization of murine ortholog (*Brms1*) of breast cancer metastasis suppressor 1 (*BRMS1*). Int J Cancer 97:15–20
  22. Samant RS, Debies MT, Hurst DR et al (2006) Suppression of murine mammary carcinoma metastasis by the murine ortholog of breast cancer metastasis suppressor 1 (*Brms1*). Cancer Lett 235:260–265
  23. Richmond A, Su Y (2008) Mouse xenograft models vs. GEM models for human cancer therapeutics. Dis Model Mech 1:78–82
  24. Welch DR (1997) Technical considerations for studying cancer metastasis in vivo. Clin Exp Metastasis 15:272–306
  25. Guy CT, Cardiff RD, Muller WJ (1992) Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 12:954–961
  26. Lin EY, Jones JG, Li P et al (2003) Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol 163:2113–2126
  27. Hurst DR, Edmonds MD, Scott GK et al (2009) Breast cancer metastasis suppressor 1 *BRMS1* up-regulates miR-146 that suppresses breast cancer metastasis. Cancer Res 69:1279–1283
  28. Weidner N (1995) Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 36:169–180
  29. Henrard D, Ross SR (1988) Endogenous mouse mammary tumor virus is expressed in several organs in addition to the lactating mammary gland. J Virol 62:3046–3049
  30. Schneider J, Gomez-Esquer F, Diaz-Gil G et al (2011) mRNA expression of the putative antimetastatic gene *BRMS1* and of apoptosis-related genes in breast cancer. Cancer Genomics Proteomics 8:195–197
  31. Ladeda V, Adam AP, Puricelli L et al (2001) Apoptotic cell death in mammary adenocarcinoma cells is prevented by soluble factors present in the target organ of metastasis. Breast Cancer Res Treat 69:39–51
  32. Cavanaugh PG, Nicolson GL (1989) Purification and some properties of a lung-derived growth factor that differentially stimulates the growth of tumor cells metastatic to the lung. Cancer Res 49:3928–3933
  33. Wyckoff JB, Wang Y, Lin EY et al (2007) Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res 67:2649–2656
  34. Wang W, Wyckoff JB, Goswami S et al (2007) Coordinated regulation of pathways for enhanced cell motility and chemotaxis is conserved in rat and mouse mammary tumors. Cancer Res 67:3505–3511
  35. Grum-Schwensen B, Klingelhofer J, Grigorian M et al (2010) Lung metastasis fails in MMTV-PyMT oncomice lacking *S100A4* due to a T-cell deficiency in primary tumors. Cancer Res 70:936–947
  36. DeNardo DG, Barreto JB, Andreu P et al (2009) CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 16:91–102
  37. Yang L, Huang J, Ren X et al (2008) Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+myeloid cells that promote metastasis. Cancer Cell 13:23–35
  38. Wiseman BS, Werb Z (2002) Stromal effects on mammary gland development and breast cancer. Science (Washington, DC) 296:1046–1049
  39. Bhowmick NA, Neilson EG, Moses HL (2004) Stromal fibroblasts in cancer initiation and progression. Nature 432:332–337
  40. Lifsted T, Le Voyer T, Williams M et al (1998) Identification of inbred mouse strains harboring genetic modifiers of mammary tumor age of onset and metastatic progression. Int J Cancer 77:640–644
  41. Qiu TH, Chandramouli GVR, Hunter KW et al (2004) Global expression profiling identifies signatures of tumor virulence in MMTV-PyMT-transgenic mice: correlation to human disease. Cancer Res 64:5973–5981
  42. Zhang Z, Yamashita H, Toyama T et al (2006) Reduced expression of the breast cancer metastasis suppressor 1 mRNA is correlated with poor progress in breast cancer. Clin Cancer Res 12:6410–6414
  43. Hicks DG, Yoder BJ, Short S et al (2006) Loss of *BRMS1* protein expression predicts reduced disease-free survival in hormone receptor negative and *HER2* positive subsets of breast cancer. Clin Cancer Res 12:6702–6708
  44. Lombardi G, Di Cristofano C, Capodanno A et al (2006) High level of messenger RNA for *BRMS1* in primary breast carcinomas is associated with poor prognosis. Int J Cancer 120:1169–1178
  45. Metge BJ, Frost AR, King JA et al (2008) Epigenetic silencing contributes to the loss of *BRMS1* expression in breast cancer. Clin Exp Metastasis 25:753–763
  46. Frolova N, Edmonds MD, Bodenshtein TM et al (2009) A shift from nuclear to cytoplasmic breast cancer metastasis suppressor 1 expression is associated with highly proliferative estrogen receptor-negative breast cancers. Tumour Biol 30:148–159